WilmerHale Advises Enavate Sciences on Its Investment in Braveheart Bio

WilmerHale Advises Enavate Sciences on Its Investment in Braveheart Bio

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Providing comprehensive solutions for the acquisition, enforcement and protection of IP.

WilmerHale advised Enavate Sciences (a platform of Patient Square Capital) on its investment in Braveheart Bio, a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related conditions, in connection with its launch and $185 million Series A financing.

The WilmerHale team was led by Palo Alto partner Daniel Zimmermann, with associate Ben Goldfein. Palo Alto partner Jekkie Kim provided advice on intellectual property and licensing matters. 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel